At a glance
ClinicalIndex Comparison RecordN/ACompleted· 3,623 enrolled
Drug / intervention
Alogliptin Benzoatedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Post Marketing Surveillance Protocol for Nesina® Tablet [Monotherapy or Combination Therapy in Type 2 Diabetic Patients]
In Brief
An observational study evaluating Alogliptin Benzoate for Type 2 Diabetes Mellitus. Completed, enrolled 3,623 participants across 22 sites.
Detailed Summary
The purpose of this study is to evaluate safety by determining the incidence rates of all adverse events (AEs) including serious adverse events (SAEs)/serious adverse drug reactions (ADRs), unexpected AEs and ADRs that are not reflected in the precautions for use, ADRs already known, non-serious ADRs and other safety related information among participants who have received alogliptin for type 2 diabetes mellitus.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesSouth Korea
Collaborators--
Timeline
N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartApr 2014
Primary CompletionAug 2019
First PostedJul 2021
TodayJul 2026
First PostedJul 28, 2021
Enrollment StartApr 19, 2014
Primary CompletionAug 30, 2019
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 4.9 years ago
Interventions
Alogliptin Benzoatedrug
Alogliptin benzoate tablets